17:41 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting DPP-8 and DPP-9 could help treat AML. In 12 human AML cell lines, the DPP-8/DPP-9 inhibitor BXCL701 or two tool compound dual DPP-8/DPP-9 inhibitors...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
16:04 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma, which...
18:23 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves CV label update for Pfizer's Celebrex

FDA approved a label supplement for Celebrex celecoxib from Pfizer Inc. (NYSE:PFE) to include data from a postmarketing cardiovascular outcomes trial showing that the lowest approved dose of Celebrex had similar CV safety to that...
18:44 , May 30, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds Selective peptidomimetic PREP inhibitors that cross the BBB could be used to probe the protein’s role in Parkinson’s disease, schizophrenia and other neurological diseases. Chemical synthesis, in vitro testing in enzyme activity...
14:44 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Pfizer's tafamidis meets in Phase III for TTR cardiomyopathy

Pfizer Inc. (NYSE:PFE) said tafamidis meglumine met the primary endpoint in the Phase III ATTR-ACT trial to treat transthyretin (TTR) cardiomyopathy. Compared with placebo, the therapy reduced a combination of all-cause mortality and frequency of...
20:30 , Mar 30, 2018 |  BC Extra  |  Clinical News

Alnylam, Ionis fall after Pfizer's TTR cardiomyopathy readout

Pfizer Inc. (NYSE:PFE) said tafamidis meglumine met the primary endpoint in the Phase III ATTR-ACT trial to treat transthyretin (TTR) cardiomyopathy. Compared with placebo, the therapy reduced a combination of all-cause mortality and frequency of...
16:46 , Mar 16, 2018 |  BC Week In Review  |  Financial News

AI play BioXcel raises $60M IPO

Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO and Canaccord Genuity. The...
19:25 , Mar 8, 2018 |  BC Extra  |  Financial News

AI play BioXcel raises $60M IPO

BioXcel Therapeutics Inc. (NASDAQ:BTAI) gained $0.03 to $11.03 Thursday after the artificial intelligence company raised $60 million through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO...
23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...